Skip to main content
NVCR
NASDAQ Industrial Applications And Services

NovoCure Receives FDA Approval for Optune Pax in Locally Advanced Pancreatic Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.5
Mkt Cap
$1.176B
52W Low
$9.82
52W High
$22.95
52W Position info
6.9% above low
Off High info
54% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NVCR is trading near its 52-week low of $9.82 (6.9% above the low).

Summary

NovoCure announced FDA approval for Optune Pax® to treat adult patients with locally advanced pancreatic cancer, marking the first new treatment in nearly 30 years for this indication and demonstrating improved overall survival.


Key Events · Product Development and Regulatory · NVCR

  • FDA Approval Granted for Optune Pax

    The U.S. Food and Drug Administration (FDA) has approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer, to be used concomitantly with gemcitabine and nab-paclitaxel.

  • First New Treatment in Decades

    This approval marks the first new treatment in nearly 30 years for locally advanced pancreatic cancer, addressing a critical unmet medical need for this highly lethal disease.

  • Positive Phase 3 Clinical Trial Results

    The approval is supported by data from the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in median overall survival (2.0-3.2 months) and a 6.1-month extension in time to pain progression for patients treated with Optune Pax.


Analysis · NVCR · Industrial Applications And Services

This FDA approval for Optune Pax® represents a major positive catalyst for NovoCure, introducing a new treatment option for locally advanced pancreatic cancer, a disease with historically poor outcomes and limited therapeutic advancements. The approval, based on statistically significant improvements in overall survival and extended time to pain progression from the Phase 3 PANOVA-3 trial, positions Optune Pax as a potentially practice-changing therapy. This significant regulatory success provides a strong counter-narrative to the recent negative news regarding the revocation of CMS billing privileges, potentially restoring investor confidence and opening a substantial new market opportunity for the company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCR was trading at $10.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.82 to $22.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $10.94 info
Change: -$3.01 (-22%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $10.94 info
Change: -$4.40 (-29%) info
Market Cap: $1.279B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $10.94 info
Change: -$3.31 (-23%) info
Market Cap: $1.279B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $10.94 info
Change: -$5.12 (-32%) info
Market Cap: $1.279B info